ArticleMolecular oncology2019
Intra-individual variation of circulating tumour DNA in lung cancer patients.
Article in Molecular oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Circulating Tumor DNA as a Biomarker in Pancreatic Cancer: Clinical Applications and Challenges.Clinical and translational gastroenterology · 2026Review
- Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non-Small-Cell Lung Cancer in the Absence of Treatment.JCO precision oncology · 2025Article
- Article
- Dynamics of methylated cell-free DNA in the urine of non-small cell lung cancer patients.Epigenetics · 2022Article
- Reporting on circulating tumor DNA monitoring in metastatic cancer-From clinical validity to clinical utility.Cancer · 2022Article
- Current and Future Clinical Applications of ctDNA in Immuno-Oncology.Cancer research · 2022Review
- Blood, toil, and taxoteres: Biological determinants of treatment-induced ctDNA dynamics for interpreting tumor response.Pathology oncology research : POR · 2022Review
- How to Obtain a High Quality ctDNA in Lymphoma Patients: Preanalytical Tips and Tricks.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Genetic landscape of breast cancer and mutation tracking with circulating tumor DNA in Chinese women.Aging · 2021Observational
- ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.Nature reviews. Clinical oncology · 2020Review
- Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.Breast cancer research and treatment · 2020Article
- Article
- Day-to-day and within-day biological variation of cell-free DNA.EBioMedicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating tumour DNA (ctDNA) has been increasingly incorporated into the treatment of cancer patients. ctDNA is generally accepted as a powerful diagnostic tool, whereas the utility of ctDNA to monitor disease activity needs to be fully validated. Central to this challenge is the question of whether changes in longitudinal ctDNA measurements reflect disease activity or merely biological variation. Thus, the aim of this study was to explore the intra-individual biological variation of ctDNA in lung cancer patients. We identified tumour-specific mutations using next-generation sequencing. Day-to-day and hour-to-hour variations in plasma concentrations of the mutant allele and wild-type cell-free DNA (cfDNA) were determined using digital PCR. The levels of the mutant alleles varied by as much as 53% from day to day and 27% from hour to hour. cfDNA varied up to 19% from day to day and up to 56% from hour to hour, as determined using digital PCR. Variations were independent of the concentration. Both mutant allele concentrations and wild-type cfDNA concentrations showed considerable intra-individual variation in lung cancer patients with nonprogressive disease. This pronounced biological variation of the circulating DNA should be investigated further to determine whether ctDNA can be used for monitoring cancer activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.